The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: A randomised, placebo-controlled, pilot study

British Journal of Ophthalmology

Volumn 101, Issue 7, 2017, Pages 926-932

  Golebiowski, Blanka ^a   Badarudin, Noor ^a   Eden, John ^a,b   Gerrand, Leanne ^a   Robinson, Jennifer ^a   Liu, Jinzhu ^b   Hampel, Ulrike ^a,c   You, Jingjing ^a,d   Stapleton, Fiona ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROYAL HOSPITAL FOR WOMEN   (Australia)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Drugs; Ocular surface; Tears

Indexed keywords

ANDROSTANEDIOL; ESTRADIOL; GLUCURONIDE; PLACEBO; PRASTERONE SULFATE; TESTOSTERONE; ANDROGEN; ESTROGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONJUNCTIVAL SENSITIVITY; CONTROLLED STUDY; CORNEA SENSIBILITY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRY EYE; ESTRADIOL BLOOD LEVEL; EYE EXAMINATION; FEMALE; GEL; HORMONE BLOOD LEVEL; HUMAN; LACRIMAL FLUID; LACRIMATION; MIDDLE AGED; MORPHOLOGY; PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SENSIBILITY; TEAR OSMOLARITY; TEAR STABILITY; TREATMENT DURATION; VISUAL SYSTEM FUNCTION; VISUAL SYSTEM PARAMETERS; CUTANEOUS DRUG ADMINISTRATION; DRUG EFFECTS; DRY EYE SYNDROMES; FOLLOW UP; MEIBOMIAN GLAND; METABOLISM; RETROSPECTIVE STUDY; SECRETION (PROCESS); TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ANDROGENS; DOUBLE-BLIND METHOD; DRY EYE SYNDROMES; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEIBOMIAN GLANDS; MIDDLE AGED; PILOT PROJECTS; POSTMENOPAUSE; RETROSPECTIVE STUDIES; TEARS; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84994812866     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2016-309498     Document Type: Article

References (37)

1. Chia EM, Mitchell P, Rochtchina E, et al. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Experiment Ophthalmol 2003;31:229-32.
2. Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136:318-26.
3. Truong S, Cole N, Stapleton F, et al. Sex hormones and the dry eye. Clin Exp Optom 2014;97:324-36.
4. Sullivan DA. Sex and sex steroid influence on dry eye syndromes. In: Pflugfelder S, Beuerman R, Stern ME, eds. Dry eye and ocular surface disease. New York City, NY: Marcel Dekker Inc., 2004:165-90.
5. Sato EH, Sullivan DA. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjogren's syndrome. Invest Ophthalmol Vis Sci 1994;35:2632-42.
6. Sullivan DA, Sullivan BD, Ullman MD, et al. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci 1994;41:3732-42.
7. Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab 2000;85:4874-82.
8. Cermak JM, Krenzer KL, Sullivan RM, et al. Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface? Cornea 2003;22:516-21.
9. Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci 2002;966:211-22.
10. Sullivan BD, Evans JE, Dana MR, et al. Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretions. Arch Ophthalmol 2006;124:1286-92.
11. Connor C, Karkkainen T. The efficacy of androgenic artificial tears in the treatment of dry eye. Optom Vis Sci 2001;78(12 Suppl):S123.
12. Connor CG. Reduction in dry eye symptoms after treatment with transdermal sex hormone creams. Optom Vis Sci 2007;84:E-abstract 075329.
13. Connor CG, Primo EJ. A weak androgenic artificial tear solution decreases the osmolarity of dry eye patients. Invest Ophthalmol Vis Sci 2001;42:S30.
14. Worda C, Nepp J, Huber JC, et al. Treatment of keratoconjunctivitis sicca with topical androgen. Maturitas 2001;37:209-12.
15. Scott G, Yiu SC, Wasilewski D, et al. Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women. Am J Ophthalmol 2005;139:1109-10.
16. Nanavaty MA, Long M, Malhotra R. Transdermal androgen patches in evaporative dry eye syndrome with androgen deficiency: a pilot study. Br J Ophthalmol 2014;98:567-9.
17. Gagliano C, Caruso S, Napolitano G, et al. Low levels of 17-β-oestradiol, oestrone and testosterone correlate with severe evaporative dysfunctional tear syndrome in postmenopausal women: a case-control study. Br J Ophthalmol 2014;98:371-6.
18. Sullivan DA, Jensen RV, Suzuki T, et al. Do sex steroids exert sex-specific and/or opposite effects on gene expression in lacrimal and meibomian glands? Mol Vis 2009;15:1553-72.
19. Suzuki T, Schirra F, Richards SM, et al. Estrogen and progesterone control of gene expression in the mouse meibomian gland. Invest Ophthalmol Vis Sci 2008;49:1797-808.
20. Mathers WD, Stovall D, Lane JA, et al. Menopause and tear function: the influence of prolactin and sex hormones on human tear production. Cornea 1998;17:353-8.
21. Versura P, Fresina M, Campos EC. Ocular surface changes over the menstrual cycle in women with and without dry eye. Gynecol Endocrinol 2007;23:385-90.
22. Golebiowski B, Badarudin N, Eden J, et al. Does endogenous serum oestrogen play a role in Meibomian gland dysfunction in postmenopausal women with dry eye. Br J Ophthalmol Published Online First: 13 Apr 2016. doi:10.1136/bjophthalmol-2016-308473
23. Schaumberg DA, Buring JE, Sullivan DA, et al. Hormone replacement therapy and dry eye syndrome. JAMA 2001;286:2114-19.
24. Shaharuddin B, Ismail-Mokhtar SF, Hussein E. Dry eye in post-menopausal Asian women on hormone replacement therapy. Int J Ophthalmol 2008;1:158-60.
25. Erdem U, Ozdegirmenci O, Sobaci E, et al. Dry eye in post-menopausal women using hormone replacement therapy. Maturitas 2007;56:257-62.
26. Sator MO, Joura EA, Golaszewski T, et al. Treatment of menopausal keratoconjunctivitis sicca with topical oestradiol. Br J Obstet Gynaecol 1998;105:100-2.
27. Akramian J, Wedrich A, Nepp J, et al. Estrogen therapy in keratoconjunctivitis sicca. Adv Exp Med Biol 1998;438:1005-9.
28. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
29. El-Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric 2007;10:335-43.
30. Fooladi E, Reuter SE, Bell RJ, et al. Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. Menopause 2015;22:44-9.
31. Jarvinen A, Granander M, Nykanen S, et al. Steady-state pharmacokinetics of oestradiol gel in post-menopausal women: effects of application area and washing. Br J Obstet Gynaecol 1997;104(Suppl 16):14-8.
32. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface diseases index. Arch Ophthalmol 2000;118:615-21.
33. Johnson ME, Murphy PJ. Measurement of ocular surface irritation on a linear interval scale with the ocular comfort index. Invest Ophthalmol Vis Sci 2007;48:4451-8.
34. Yamaguchi M, Kutsuna M, Uno T, et al. Marx line: fluorescein staining line on the inner lid as indicator of meibomian gland function. Am J Ophthalmol 2006;141:669-75.
35. Chao C, Stapleton F, Badarudin E, et al. Ocular surface sensitivity repeatability with Cochet-Bonnet esthesiometer. Optom Vis Sci 2015;92:183-9.
36. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011;151:792-8.e1.
37. Kuscu NK, Toprak AB, Vatansever S, et al. Tear function changes of postmenopausal women in response to hormone replacement therapy. Maturitas 2003;44:63-8.